Literature DB >> 12381505

Ankylosing spondylitis: introductory comments on its diagnosis and treatment.

M A Khan1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12381505      PMCID： PMC1766733          DOI： 10.1136/ard.61.suppl_3.iii3

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  60 in total

1.  Functional disability predicts total costs in patients with ankylosing spondylitis.

Authors:  Michael M Ward
Journal:  Arthritis Rheum       Date:  2002-01

2.  Predicting outcome of ankylosing spondylitis: prognosis or hindsight?

Authors:  M Boers
Journal:  J Rheumatol       Date:  1994-10       Impact factor: 4.666

3.  Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease.

Authors:  S H Murch; C P Braegger; J A Walker-Smith; T T MacDonald
Journal:  Gut       Date:  1993-12       Impact factor: 23.059

4.  Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy.

Authors:  Filip Van Den Bosch; Elli Kruithof; Dominique Baeten; Annemie Herssens; Filip de Keyser; Herman Mielants; Eric M Veys
Journal:  Arthritis Rheum       Date:  2002-03

5.  Measures to assess ankylosing spondylitis: taxonomy, review and recommendations.

Authors:  C Bakker; M Boers; S van der Linden
Journal:  J Rheumatol       Date:  1993-10       Impact factor: 4.666

6.  Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis.

Authors:  J Braun; M Bollow; L Neure; E Seipelt; F Seyrekbasan; H Herbst; U Eggens; A Distler; J Sieper
Journal:  Arthritis Rheum       Date:  1995-04

7.  Disease severity in rheumatoid arthritis: relationships of plasma tumor necrosis factor-alpha, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures.

Authors:  J C Beckham; D S Caldwell; B L Peterson; A M Pippen; M S Currie; F J Keefe; J B Weinberg
Journal:  J Clin Immunol       Date:  1992-09       Impact factor: 8.317

Review 8.  Management of refractory ankylosing spondylitis and related spondyloarthropathies.

Authors:  B Amor; M Dougados; M A Khan
Journal:  Rheum Dis Clin North Am       Date:  1995-02       Impact factor: 2.670

9.  A comparative study of nabumetone and indomethacin in ankylosing spondylitis.

Authors:  T G Palferman; M Webley
Journal:  Eur J Rheumatol Inflamm       Date:  1991

10.  Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study.

Authors:  M Dougados; S vam der Linden; M Leirisalo-Repo; B Huitfeldt; R Juhlin; E Veys; H Zeidler; T K Kvien; I Olivieri; B Dijkmans
Journal:  Arthritis Rheum       Date:  1995-05
View more
  16 in total

1.  Postural deformities: potential morbidities to cause balance problems in patients with ankylosing spondylitis?

Authors:  Ece Çınar; Yeşim Akkoç; Hale Karapolat; Raika Durusoy; Gökhan Keser
Journal:  Eur J Rheumatol       Date:  2015-08-21

2.  Ankylosing spondylitis and undifferentiated spondyloarthritis in Kuwait: a comparison between Arabs and South Asians.

Authors:  S S Uppal; Mini Abraham; R I Chowdhury; Rakesh Kumari; E M Pathan; A Al Rashed
Journal:  Clin Rheumatol       Date:  2005-10-21       Impact factor: 2.980

3.  Relationship between diagnosis delay and disease features in Moroccan patients with ankylosing spondylitis.

Authors:  Yousra Ibn Yacoub; Bouchra Amine; Assia Laatiris; Rachida Bensabbah; Najia Hajjaj-Hassouni
Journal:  Rheumatol Int       Date:  2010-11-26       Impact factor: 2.631

4.  Efficacy of SLZ and MTX (alone or combination) on the treatment of active sacroiliitis in early AS.

Authors:  Yasemin Kabasakal; Gul Kitapcioglu; Figen Yargucu; Ali Taylan; Mehmet Argin; Gurbuz Gumusdis
Journal:  Rheumatol Int       Date:  2009-07-11       Impact factor: 2.631

5.  How to diagnose axial spondyloarthritis early.

Authors:  M Rudwaleit; D van der Heijde; M A Khan; J Braun; J Sieper
Journal:  Ann Rheum Dis       Date:  2004-05       Impact factor: 19.103

6.  Serum hyaluronic acid levels in patients with ankylosing spondylitis.

Authors:  Mehmet Tuncay Duruöz; Yasemin Turan; Lale Cerrahoglu; Banu Isbilen
Journal:  Clin Rheumatol       Date:  2007-10-23       Impact factor: 2.980

7.  Diagnosis delay in patients with ankylosing spondylitis: factors and outcomes--an Indian perspective.

Authors:  Rohit Aggarwal; Anand N Malaviya
Journal:  Clin Rheumatol       Date:  2008-12-04       Impact factor: 2.980

8.  LLLT for the management of patients with ankylosing spondylitis.

Authors:  D Stasinopoulos; K Papadopoulos; D Lamnisos; A Stergioulas
Journal:  Lasers Med Sci       Date:  2016-01-21       Impact factor: 3.161

9.  The investigation of sacroiliitis with different imaging techniques in spondyloarthropathies.

Authors:  N Inanc; P Atagündüz; F Sen; T Biren; H T Turoğlu; H Direskeneli
Journal:  Rheumatol Int       Date:  2004-08-12       Impact factor: 2.631

10.  Knowledge of features of inflammatory back pain in primary care in the West Midlands: a cross-sectional survey in the United Kingdom.

Authors:  T Adizie; S Elamanchi; A Prabu; A V Pace; R Laxminarayan; N Barkham
Journal:  Rheumatol Int       Date:  2018-07-19       Impact factor: 2.631
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.